share_log

Senti Biosciences | 8-K: Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights

SEC announcement ·  Mar 21 16:19
Summary by Moomoo AI
On March 21, 2024, Senti Biosciences, Inc., a biotechnology company specializing in cell and gene therapies, announced its financial results for the year ended December 31, 2023. The company, which is based in South San Francisco, California, and incorporated in Delaware, reported a net loss of $71.1 million, or $1.60 per share, for the year, compared to a net loss of $58.2 million, or $2.23 per share, in the previous year. The net loss included a non-recurring gain from discontinued operations and an impairment related to the GeneFab transaction. Senti Biosciences achieved significant milestones in 2023, including the clearance of its first Investigational New Drug application for SENTI-202, a potential treatment for acute myeloid leukemia (AML), and the establishment of strategic collaborations for clinical development in China and...Show More
On March 21, 2024, Senti Biosciences, Inc., a biotechnology company specializing in cell and gene therapies, announced its financial results for the year ended December 31, 2023. The company, which is based in South San Francisco, California, and incorporated in Delaware, reported a net loss of $71.1 million, or $1.60 per share, for the year, compared to a net loss of $58.2 million, or $2.23 per share, in the previous year. The net loss included a non-recurring gain from discontinued operations and an impairment related to the GeneFab transaction. Senti Biosciences achieved significant milestones in 2023, including the clearance of its first Investigational New Drug application for SENTI-202, a potential treatment for acute myeloid leukemia (AML), and the establishment of strategic collaborations for clinical development in China and manufacturing partnerships. The company has prioritized the clinical development of SENTI-202 and SENTI-301A, expecting to begin dosing patients in the second quarter of 2024. Senti Biosciences ended the year with $35.9 million in cash and short-term investments, and with additional receivables from GeneFab, anticipates funding operations into the first quarter of 2025. Research and development expenses increased to $32.2 million from $28.1 million in the previous year, while general and administrative expenses slightly decreased. The company's stock is traded on the Nasdaq Capital Market under the symbol SNTI.

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more